Haleon (HLN) Gross Margin (2021 - 2025)

Haleon's (HLN) quarterly Gross Margin came in at 64.31% in Q4 2025, up 4.24% on a QoQ basis from 61.69% in Q4 2023.

Haleon (HLN) Gross Margin (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Gross Margin data on file, last reported at 64.31% in Q4 2025.

Quarterly Gross Margin changed N/A year-over-year to 64.31% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 62.51% (changed N/A YoY) and the FY2025 annual result came in at 64.19%, up 344.0% from the prior year.
Gross Margin grew to 64.31% in Q4 2025, from 61.69% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 191.47% in Q4 2022 to a low of 61.62% in Q2 2023.
A 4-year average of 83.85% and a median of 62.0% in 2021 frame the typical range for Gross Margin.
Annual changes were most pronounced in 2022 — Gross Margin jumped 12960 bps — and 2023, when it tumbled 12978 bps.
Tracing HLN's Gross Margin over 4 years: stood at 61.87% in 2021, then soared by 209 bps to 191.47% in 2022, then slumped by 68 bps to 61.69% in 2023, then advanced by 4 bps to 64.31% in 2025.
The last three Gross Margin figures came in at 64.31% (Q4 2025), 61.69% (Q4 2023), and 62.14% (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	51.98%
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	42.63%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	66.66%
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	87.30%
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	38.77%
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	97.58%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	58.33%
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn	80.22%

Download Data